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 ABSTRACT OF THESIS  
 
 
THE ROLE OF STEM CELL ANTIGEN-1(Sca-1) IN MUSCLE AGING 
 
Muscle aging is associated with a decrease in the number of satellite cells and their 
progeny, muscle progenitor cells (MPCs) that are available for muscle repair and 
regeneration. However, there is an increase in non-immuno-hematopoietic cells (CD45 
negative) in regenerating muscle from aged mice characterized by high stem cell antigen 
-1(Sca-1) expression. In aged regenerating muscle, 14.2% of cells are CD45
neg
 Sca-1
pos
 
while 7.2% of cells are CD45
neg 
Sca-1
pos
 in young adult muscle. In vitro, CD45
neg 
Sca-1
pos
 
cells over express genes associated with fibrosis, potentially controlled by Wnt2. These 
cells are proliferative, non-myogenic and non-adipogenic, and arise in clonally-derived 
MPCs cultures from aged mice. Both in vitro and in vivo studies suggest that CD45
neg
 
Sca-1
pos
 cells from aged muscle are more susceptible to apoptosis than their MPCs, which 
may contribute to depletion of the satellite cell pool. Therefore, with age, a subset of 
MPCs takes on an altered phenotype, which is marked by high Sca-1 expression. This 
altered phenotype prevents these cells from participating in muscle regeneration or 
replenishing the satellite cell pool, and instead may contribute to fibrosis in aged muscle.    
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   CHAPTER 1 
 Introduction 
Stem Cells 
 There are approximately 10-100 trillion cells in an average human body. Stem 
cells are rare cells, approximately 5 x 10
4
 per tissue is found in all multi-cellular 
organisms (Kindt 2007). These uniquely unspecialized cells are capable of self renewal 
through mitotic cell division and give rise to a diverse range of differentiated and 
specialized cell types that are needed to maintain tissue growth, homeostasis, and repair 
throughout an organism’s life span (Till and Mc 1961). The two main types of 
mammalian stem cells are: embryonic stem cells that are found in blastocysts and adult 
stem cells that are found in adult tissues (Cheng 2008). Embryonic stem cells can 
differentiate into all types of specialized embryonic tissues and are thus considered to be 
totipotent. Pluripotent adult stem cells, identified in essentially all mammalian tissues, 
can give rise to many differentiated cells types and have been hypothesized to have the 
capacity to differentiate outside their
 
tissue of origin (Krtolica 2005; Shizuru, Negrin et 
al. 2005).  
Adult stem cells reside in a variety of locations throughout the body and may 
remain quiescent (non-dividing) for many years until they are activated by disease or 
tissue injury (Weissman 2000; Kenyon and Gerson 2007). Upon activation, stem cells 
can undergo either symmetric or asymmetric cell divisions (Fuller 2006; Holmes and 
Stanford 2007). In symmetric cell division, either two new stem cells or two 
differentiating cells are produced. In contrast, asymmetric cell division, results in one 
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new stem cell, which either may return to quiescence or continue to divide, and a 
progenitor cell, which is more restricted in differentiation potential, often referred to as 
multipotent. Progenitor cells typically proliferate, and depending on environmental cues, 
specialize into the appropriate differentiated cell type.  Finally, stem cells may also 
undergo apoptosis, resulting in depletion of the stem cell pool. Detailed studies involving 
stem cells from bone marrow, peripheral blood, blood vessels, skeletal muscle, skin, and 
liver have shown that upon manipulation in vitro, they can be induced to differentiate into 
a number of different cell types (Weissman 2000; McKinney-Freeman 2002). 
Regenerative medicine is based on the development of these techniques to control stem 
cell fate so that they may be used to treat many serious diseases. 
Hematopoietic Stem Cells  
Hematopoietic stem cells (HSCs) are the best characterized adult stem cell population 
(Wilson and Trumpp 2006; Huang, Cho et al. 2007). HSCs, which are derived from 
whole bone
 
marrow, have been shown to be capable of contributing to the regeneration of 
skeletal
 
muscle, cardiac muscle, liver, and multiple
 
epithelial tissues (McKinney-Freeman 
2002; Wong, Lowes et al. 2007). However, due to the rarity of HSCs, which account for 
less than 0.5% of a mouse bone marrow cells, the identification and isolation of pure 
populations of HSCs in sufficient numbers has been challenging (Spangrude, Heimfeld et 
al. 1988; Harrison, Astle et al. 1989; Muller-Sieburg and Riblet 1996; Reya, Morrison et 
al. 2001; Kamminga and de Haan 2006). For many years, HSC properties were inferred 
from cell-based tissue repair assays (Montarras, Morgan et al. 2005; Shizuru, Negrin et 
al. 2005). More recently, with the development of specific antibodies against cell surface 
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antigens, researchers have been able to isolate and identify HSCs from both mouse and 
human.  Identification of unique markers on the surface of HSCs provided the basis for 
the Fluorescence-Activated Cell Sorting (FACS) technique, by far the most effective and 
most widely used method for identification and isolation of stem cells (Spangrude, 
Heimfeld et al. 1988; Shizuru, Negrin et al. 2005; Wong, Lowes et al. 2007; Cheng 
2008).  
One of the
 
markers whose expression defines HSCs in mice is stem cell antigen-1 
(Sca-1). The Sca-1 gene is found on chromosome 15 and is a Ly-6A/E member of the Ly-
6 multigene family of glycosyl phosphatidylinositol (GPI)-anchored membrane proteins, 
originally identified as an antigen upregulated on activated lymphocytes (Spangrude, 
Aihara et al. 1988; Spangrude, Heimfeld et al. 1988; Miles, Sanchez et al. 1997; 
Bradfute, Graubert et al. 2005; Holmes and Stanford 2007). It is regulated
 
in a complex 
fashion during hematopoietic cell differentiation. (A detailed discussion of the 
progression of HSC restriction and differentiation is presented in Chapter 2 under Stem 
Cell Hierarchy.)  The expression of Sca-1 is down regulated (Akashi, Traver et al. 2000) 
as
 
HSCs differentiate into common myeloid progenitors (CMPs) which
 
give rise to 
monocytes and macrophages, neutrophils, basophils eosinophils, erythrocytes, 
megakarocytes. As HSCs commit to the lymphoid progenitors, which give rise to T, B, 
and natural killer (NK) cells, Sca-1 expression is decreased (Kondo, Weissman et al. 
1997; Ito, Li et al. 2003).  Sca-1 expression is turned off
 
at an early stage of thymocyte 
differentiation, and then re-expressed
 
on
 
mature single-positive medullary thymocytes 
and peripheral
 
T cells (Bamezai 2004). The expression is further upregulated in activated 
lymphocytes (van de Rijn, Heimfeld et al. 1989). Expression of Sca-1 occurs outside the 
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hematopoietic system in the form of stem, progenitor and differentiated cell types in a 
wide variety of tissues and organs, which makes it ideal for routine use in combination 
with negative selection against mature markers for enrichment of stem and progenitor 
cells (Bamezai 2004; Holmes and Stanford 2007). The  in vivo  functions of Sca-1 are 
unknown, however, in vitro studies suggest that it plays a key role in cellular activation 
(Gumley, McKenzie et al. 1995). 
  
CD45, also known as the common leukocyte antigen, (T220 and B220 in mice) is 
a protein tyrosine phosphatase located in all hematopoietic cells except erythrocytes and 
platelets (Thomas 1989; Barford, Flint et al. 1994; Goodell, Brose et al. 1996; Gussoni, 
Soneoka et al. 1999).  This protein has several isoforms and HSCs express one or more of 
these isoforms at specific stages of differentiation. CD45 is uniformly distributed in 
plasma membrane, constituting 10% of the cell surface protein of T cell and B cells, and 
facilitates signal transduction and cell activation (Virts, Barritt et al. 1997). It has been 
used as an exclusive marker of the immuno- hematopoietic lineage. 
 
 Another cell surface marker, CD34, is a transmembrane cell surface 
glycoprotein; it is known to be selectively expressed within the human (Civin, Strauss et 
al. 1984; Katz, Tindle et al. 1985) and murine (Baumheter, Singer et al. 1993; Krause, Ito 
et al. 1994) hematopoietic systems on stem and progenitor cells. It has been shown to 
play a role in adhesion and differentiation control. However, as the cells mature the 
expression of CD34 is lost (Wood 1997). Although it is commonly  known as 
hematopoietic progenitor antigen it is also expressed on other cells, such as muscle stem 
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cells (see below), vascular endothelial cells (Fina, Molgaard et al. 1990; Baumheter, 
Singer et al. 1993) and  certain classes of fibroblasts (Suda, Sudo et al. 1992) but it has 
been used most widely for enumeration and purification of HSCs.  
 
Skeletal Muscle Stem Cells 
Skeletal muscle is subjected to constant injury resulting from weight bearing, 
exercise, and trauma. Therefore, muscle requires an ever-available renewable source of 
cells for repair and regeneration. Satellite cells, quiescent muscle stem cells, reside 
beneath the basal lamina surrounding each myofiber, and are primarily responsible for 
postnatal muscle growth and repair (Bischoff and Heintz 1994; Bodine-Fowler 1994; 
Cossu and Biressi 2005; Shefer, Van de Mark et al. 2006). When freshly isolated satellite 
cells or intact myofibers are transplanted with their associated satellite cells to irradiated 
hosts, satellite cells can self-renew, replenish a depleted niche, and their progeny are 
capable of efficient regeneration of myofibers (Morgan, Hoffman et al. 1990; Gussoni, 
Soneoka et al. 1999; Kamminga, Akkerman et al. 2000; Partridge 2002; Kamminga, van 
Os et al. 2005; Fukada, Uezumi et al. 2007).  However, satellite cells remain dormant in 
mature muscle and only enter the cell cycle in response to injury.  The identification of 
markers of satellite cells lags behind HSCs, but they do express CD34
+
 cell surface 
marker and the paired-box transcription factor (Pax7). This transcription factor is 
specifically expressed in quiescent and newly activated satellite
 
cells and plays a key role 
in controlling myogenic differentiation (Grounds and Yablonka-Reuveni 1993; 
Yablonka-Reuveni and Rivera 1994; Zammit, Heslop et al. 2002).  
 6 
 
Pax7 is also important for cell survival, having anti-apoptotic functions. The 
absence of myogenic satellite cells in young Pax7
–/– 
skeletal muscle demonstrates a 
requirement for Pax7 in the function
 
of the satellite cell lineage (Seale, Sabourin et al. 
2000; Kuang 2006). Once activated, satellite cells proliferate extensively, and generate a 
pool
 
of muscle progenitor cells (MPCs) which subsequently fuse and differentiate. In 
cases of minimal muscle damage, MPCs fuse with existing myofibers to repair them, 
which can result in hypertrophy upon repeated damage. Upon massive damage, MPCs 
fuse with each other to form new myofibers that replace those lost during degeneration.  
As the cycle begins and satellite cells are activated, they rapidly initiate expression of the 
myogenic regulatory factors (MRFs), MyoD and Myf5, which is accompanied by 
downregulation of CD34 and Pax7 (F. P. Moss 2005; Le Grand and Rudnicki 2007; Ueno 
and Weissman 2007).  
The sequential activation of MRFs and repression of Pax7 is necessary for the 
progression of MPCs through myogenic differentiation (Cooper, Tajbakhsh et al. 1999; 
Le Grand and Rudnicki 2007).  A small fraction of activated satellite cells will exit the 
cell cycle and return to the quiescent satellite cell state during muscle regeneration to 
maintain their numbers and the regenerative capacity of the muscle (Zammit, Relaix et al. 
2006). Activated satellite cells destined to return to the quiescent satellite cell pool have 
been putatively identified as cells that lose MyoD or Myf5 expression and maintain Pax7 
expression (Megeney, Kablar et al. 1996; McKinnell, Ishibashi et al. 2008).  Sca-1 also 
shows heterogeneity in expression in activated satellite cells and it has been proposed that 
Sca-1 is present on satellite cells that will self-renew as opposed to those that will give 
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rise to MPCs (Mitchell, Mills et al. 2005; Fukada, Uezumi et al. 2007; Le Grand and 
Rudnicki 2007). 
Aging in Stem Cells 
Aging has been associated with qualitative and quantitative
 
changes in stem cells. 
HSC aging has been linked to a slower and
 
incomplete response to hematopoietic stress, 
such that mature blood and immune cells are no longer produced at the same rate at 
which they are lost.  The age-dependent decline in the activities and/or number of HSCs 
has been proposed to contribute to decreased immunity (Linton and Dorshkind 2004), 
increased incidence of bone marrow failure (Lichtman and Rowe 2004), hematological 
neoplasia (Lichtman and Rowe 2004), and moderate anemia (Beghe, Wilson et al. 2004; 
Guralnik, Eisenstaedt et al. 2004), all common effects of aging that occur in humans. 
Experimentally, the ability of HSCs to home and engraft the bone marrow is significantly 
diminished with age (Lorenzon, Bandi et al. 2004). However, some studies reported that 
although HSC function clearly declines with age, the number of HSCs does not 
necessarily decline. In some strains of mice, the number of HSC actually expands with 
advancing age and this age-dependent expansion of HSCs is a transplantable, cell-
autonomous property (Morrison, Wright et al. 1997; Mitchell, Mills et al. 2005; Roeder, 
Kamminga et al. 2005; Kamminga and de Haan 2006; Chambers, Shaw et al. 2007; 
Sharpless and DePinho 2007). 
Aging in skeletal muscle is associated with a significant decline in mass, strength, 
and endurance in both human and animal models (Cartee 1995; Musaro, McCullagh et al. 
1999; Karakelides and Nair 2005). Fewer myofibers are present in aged compared to 
young adult muscle and those remaining are atrophied and show increased susceptibility 
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to contraction-induced injury (Edstrom and Ulfhake 2005; Zammit 2006; Zammit, Relaix 
et al. 2006). Muscle regeneration is impaired with age and it has been proposed to be the 
result of impaired satellite cell function, as well as a decrease in satellite cell number 
(Shefer, Van de Mark et al. 2006). Preliminary data from Dr. Peterson’s laboratory 
suggest that Sca-1 expression increases in aged MPCs in vivo and  in vitro (Hidestrand 
2008 in press). This is in contrast to HSCs where Sca-1 deficiency appears to hasten age 
associated changes in stem cells (Holmes and Stanford 2007). Therefore the goal of this 
project was to characterize Sca-1 expressing cells in muscle as a function of age. 
Research Question (Hypothesis) 
Sca-1 is a HSC marker that is not expressed in quiescent muscle satellite/stem cells.  
However, it is expressed in a subset of MPCs in young adult muscle and it has been 
proposed to identify MPCs that will return to the quiescent satellite cell pool. Sca-1 
expressing cells appear more abundant in aged muscle but appear to lack myogenic 
differentiation capacity. Therefore, I set out to test the hypothesis that Sca-1 marks a 
unique population of non-immuno-hematopoietic cells that increases in abundance in 
aged muscle that may contribute to impaired muscle regeneration potential during aging. 
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CHAPTER 2 
Background/Literature Review 
Adult Stem Cells 
Stem cell research began in the 1960s, when researchers discovered that stem 
cells were able to self renew and give rise to one or more progeny (Till and Mc; Becker, 
Mc et al. 1963; Siminovitch, McCulloch et al. 1963). This description of adult stem cells 
continues to be the  definition of choice, even  in the 21
st
 century, as current  researchers 
continue to show that the hallmarks of stem cells are: self-renewal, capacity to maintain 
the frequency of stem cells in a given tissue and differentiation to maintain that tissue’s 
physiological function (Krtolica 2005). These attributes are found to be important in both 
tissue repairs after injury and during the normal process of aging (Lorenzon, Bandi et al. 
2004; Rando 2006; Bellantuono and Keith 2007). Scientists have found adult stem cells 
in many more tissues than was once thought possible, maintaining regenerative organs, 
such as blood, skin, liver, skeletal muscle and intestinal tissue (Wong, Lowes et al. 2007). 
This has led scientists to contemplate whether adult stem cells could be the gold standard 
for treating many devastating diseases. 
 
Therapeutic Potential of Adult Stem Cells 
The therapeutic potential of embryonic stem cells remains limited at this time due 
to ethical concerns and the lack of federal funding for research. However, adult stem cell 
research is fast becoming center stage in the biomedical field as a potential therapeutic 
tool. Therefore understanding the basic biological properties of mammalian stem cells is 
of paramount importance. The main driving force for stem cell research is the growing 
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demand for regenerative medicine, which offers hope for the treatment of many 
devastating degenerative diseases such as diabetes, Parkinson's disease, and Alzheimer's 
disease (McKinney-Freeman 2002; Wong, Lowes et al. 2007). Cell therapy has also been 
explored for muscle degenerative diseases such as Duchenne muscular dystrophy (DMD) 
and muscle atrophy during aging (sacropenia) (Ivanova, Dimos et al. 2002; Cheng 2008). 
Satellite cells and their progeny, known to play a role in muscle growth and 
regeneration are the primary cells types used for treating muscular dystrophies (Sebille 
2005). From clonal analysis (monitor the progeny of individual cells), it was revealed that 
the yield and proliferative capacity of MPCs in DMD was down regulated. From the total 
number of MPCs obtained per gram of dystrophic muscle, only approximately 5 % were 
normal. This contributes to a large proportion (95%) of the cells that remain to give rise 
to clones of cells with altered cell morphology, increased doubling times, and poor 
growth potential leading to severely impaired muscle growth. (Pavlath, Thaloor et al. 
1998). Normally, satellite cells can fully regenerate chemically destroyed myofibers at 
least 12 times in succession in vivo, while human MPCs give rise to an average of 10
8
 
progeny in vitro (Blau and Webster 1981). This proliferative potential is not just reserved 
for muscle regeneration but is also utilized for muscle growth.  A 6-fold increase in 
muscle fiber diameter occurs in the first 13 years of human life, which is paralleled by an 
increase in the number of nuclei per unit fiber (Brooke and Engel 1969). Similar 
increases in the size and nuclear number of muscle fibers accompanies postnatal 
development in the mouse (Cardasis and Cooper 1975). Due to the absence of nuclear 
division within differentiated multinucleated myofibers, the additional nuclei must be 
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exogenous in origin and contributed by the division and fusion of adjacent satellite cells/ 
MPCs (Stockdale and Holtzer 1961; Blau, Webster et al. 1983). 
 Presently scientists in many laboratories are trying to find ways to grow adult 
stem cells in cell culture and manipulate them to generate specific cell types so they can 
be used to treat injury or disease. In the case of neurodegenerative diseases, potential 
treatments include replacing the dopamine-producing cells in the brains of Parkinson's 
patients (Stredrick, Stokes et al. 2004) and hippocampal neurons in Alzheimer’s patients 
(Kelly and Ferreira 2007); for type I diabetes, developing insulin-producing cells 
(Zulewski 2007); and for the cardiovascular system, replacing scarred heart muscle 
following a heart attack (Dalton 2008). Hematopoietic stem cells (HSCs) are perhaps the 
best characterized adult stem cell population and have been used most successfully for 
therapeutic purposes (Wilson and Trumpp 2006). HSC transplantation (HSCT) can cure 
or treat hematopoietic failures, immune deficiencies, leukemias and certain other cancers 
(Cheng 2008). The two major types of HSCT are autologous and allogeneic, which are 
defined by the donor graft source. In autologous HSCT, the patients undergo 
myeloablative doses of chemotherapy and/or radiation designed to remove all 
malignancies from the body. These patients have a malignancy that has either proven to 
be resistant to the standard chemotherapy or considered to be high risk for relapse even 
though complete remission may have been achieved (Shizuru, Negrin et al. 2005). The 
doses given to patients are very high and the bone marrow is ablated in the process. 
Therefore the patient must undergo a bone marrow harvest of their own stem cells prior 
to treatment and complete their regimen with transplantation. However, only a fraction of  
patients are cured using autologous HSCT because in many patients, the disease recurs as 
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the HSCs of patients with leukemia are often contaminated with cancer-initiating cells or 
so-called cancer stem cells (see Stem Cell Hierarchy section, below). In 2000, three 
separate clinical trials were carried out for patients with multiple myeloma (Michallet, 
Philip et al. 2000), non-Hodgkin's lymphoma (Vose, Zhang et al. 2001), and metastatic 
breast cancer (Negrin, Atkinson et al. 2000). The goal of the trials was to purify HSCs, 
and thereby reduce the burden of occult malignant cells.  In all three diseases, harvested 
bone marrow (BM) or mobilized peripheral blood (MPB) were known to contain a 
significant percentage of contaminated malignant cells.  Reports from the studies showed 
that purified HSCs resulted in excellent removal of the tumor cells. 
Allogeneic HSCT is also used for high risk, relapsed or chemotherapy refractory 
malignancies, especially in patients with early hematopoietic progenitor cancer such as 
chronic myeloid leukemia (CML) or bone marrow failure states (aplastic anemia). These 
patients undergo myeloablative doses of chemotherapy and/or radiation and then are 
transplanted with stem cells from an allogenic donor.  These are members from the same 
species that are genetically different, but are matched at the human leukocyte antigen 
(major histocompatibility complex), called H2 in  mouse, a complex of genes encoding 
cell surface molecules that are required for antigen presentation to T cells and  the cause 
of graft rejection. The allogeneic HSCT patient is at risk for graft-versus-host-disease 
primarily because the transplant is not genetically identical and they contain mature 
immune cells that can respond against the host-specific antigens and cause graft- versus 
host  rejection (Shizuru, Negrin et al. 2005). For both autologous and allogeneic HSCT, 
chemotherapy and/or radiation may not eradicate the resident cancer stem cell (see Stem 
Cell Hierarchy section below), which renders the diseases essentially incurable.  For 
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example, in CML, a well known HSC cancer, Bcr-Abl tyrosine kinase inhibitors have 
been used as the first-line treatment (Druker 2002). Although HSCT is successful, CML 
can recur after long periods of remission due to reactivation of a dormant cancer stem cell 
(Ren and Mu 2005). Bone marrow or mobilized peripheral blood are the most commonly 
used sources of HSCs for transplantation in the treatment of leukemia and is most 
effective when the leukemia is in remission. However, there is an alternative source of 
allogenic HSCs, human umbilical cord blood (UCB). It has been identified to contain a 
rich source of primitive HSCs (Gluckman and Locatelli 2000). However, this type of 
transplant is especially important for patients unable to match either related or unrelated 
donors (Hofmeister, Zhang et al. 2007). It improves donor availability for transplantation 
because frozen and stored UCB can be made available on demand. Infectious agents, 
such as cytomegalovirus (CMV), are rarely found in the new born compared to adults. 
UCB cell transplants have a lower incidence and severity of GVHD than conventional 
BMT, allowing successful transplantation in the HLA-mismatched recipient (Mao, Wang 
et al. 2004). However, due to the limited sample size which results in low number of 
HSCs, it is primarily used for pediatric patients (Hofmeister, Zhang et al. 2007).   
Stem cell research has also played a key role in gene therapy, a technique for 
correcting defective genes responsible for disease development or delivering a 
therapeutic gene product (Bordignon and Roncarolo 2002). Due to their self-renewing 
and differentiation properties, HSCs are ideal vehicles for delivery of therapeutic 
transgenes for expression in their progeny. Examples of success using combinational 
stem cell and gene therapies to treat inherited disorder are: adenosine deaminase in 
deficient patients and myoblast therapy for delivery of dystrophin (Payne, Oshima et al. 
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2005; Sebille 2005), the missing gene in DMD. Cellular cardiomyoplasty, a procedure 
involving the transplantation of exogenous cells into the heart to regenerate diseased 
myocardium, has also been used deliver therapeutic genes, and improve cardiac function 
(Bonaros, Rauf et al. 2007). Vascular endothelial growth factor (VEGF) is known to play 
a key role in blood vessel formation and the mobilization of stem cells from the bone 
marrow. It   has been delivered to exert a  mitogenic effect on cardio- myocytes (Springer 
2002).  
 
Stem Cell Hierarchy 
Due to their ability to self renew, adult stem cells are maintained at roughly stable 
levels throughout adult life. However, when there is an increased demand for a particular 
cell type, stem cells divide and go through a series of specializations such that the initial 
pluripotent stem cell gives rise to progeny with differing proliferative capacities and 
increasingly restricted potential (Uher 2000). This has been most thoroughly described 
for HSCs, where it has been shown that in mice, one HSC can completely restore the 
erythroid population and the immune system following irradiation, while in humans, less 
than 10% of a donor’s total volume of bone marrow can provide enough HSCs to 
completely restore the recipient’s hematopoietic system (Kindt 2007) .   
  In mice, bone marrow cells are sub- divided into long-term self renewing HSCs 
(LT-HSCs), short-term self-renewing HSCs (ST-HSCs) and multipotent progenitors 
(MPPs) that lack self- renewal properties. The LT-HSCs give rise to the ST-HSCs, which 
give rise to the MPPs (Weissman 2000). Highly purified HSCs can be isolated by FACS 
using the cell surface
 
markers c-kit
+
 Thy-1.1
low
 lineage
/low
 Sca-1 
pos 
(Christensen and 
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Weissman 2001). LT-HSCs fulfill the criteria of HSCs due their ability to give rise to the 
lymphoid and myeloid lineages indefinitely after transplantation into lethally irradiated 
recipients. ST-HSCs have more limited self-renewal capacity and are capable of giving 
rise to these lineages for 8–12 weeks (Zipori and Honigwachs-Sha'anani 1992; 
Christensen and Weissman 2001). The MPPs then further sub-divide to form progenitor 
cells that become committed to either common myeloid progenitors (CMPs) or common 
lymphoid progenitors (CLPs). The myeloid progenitor cells differentiate to form either 
granulocyte/macrophage progenitors (GMPs) or erythroid/megakaryotic progenitor cells 
(MEPs). The GMPs terminally differentiate to form dendritic cells, granulocytes and 
macrophages, while the MEPs terminally differentiate to form erythrocytes and 
megakarocytes. Similarly, CLPs differentiate to form dendritic cells, Pro-B progenitors, 
Pro-T progenitors and Pro-NK progenitors. These progenitors finally form mature B 
cells, T cells and Natural Killer cells, respectively (Morrison, Shah et al. 1997). In young 
adult mice, approximately 8% of the LT-HSCs enter cell division per day randomly, 
however half their progeny must remain LT-HSCs to maintain the steady state level 
(Weissman 2000).  
This elaborate hierarchy has important implications for cancer biology. As DNA 
replication is prone to error, cell division provides the opportunity for the genome to 
suffer mutations, some of which may result in cancer.  Stem cells have a long life span 
with the ability to survive in severe environments, to stay quiescent in the G0 phase of the 
cell cycle most of the time, and to self-renew, making them susceptible to accumulation 
of mutations over time potentially leading to formation of a true cancer stem cell (CSC) 
(Cheng 2008). However, in the hematopoietic system, keeping the number of LT-HSCs 
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low and their frequency of division low, the chance of a catastrophic event leading to 
formation of a true CSC is also  low (Kindt 2007).  
The confinement of rapid proliferation to ST-HSCs and MPPs with limited life 
span and limited self-renewal capability, assures that mutations in these cells will likely 
not give rise to new cancer.  The current stem cell theory of cancer postulates that only 
CSCs, not most of the remaining constituent cancer cells, are responsible for 
tumorigenesis, progression, and metastasis (Komuro, Saihara et al. 2007). The CSCs can 
generate their descendants, including progenitors and relatively differentiated cancer 
cells, producing the heterogeneity of the cancer. Further, CSCs survive conventional 
anticancer therapies that target only the rapidly dividing cancer cells, whereas their 
descendants (most remaining constituent cancer cells) are killed, which may be strongly 
related to treatment failure, as well as cancer relapse (Asakura, Seale et al. 2002). It 
should also be noted that the key for homeostatic regulation of stem cells depends on the 
dynamic niche maintaining a balance between proliferation signals and anti-proliferation 
signals. Any genetic mutation that leads stem cells to become independent of growth 
signals, or to resist antigrowth signals, will cause the stem cells to undergo uncontrolled 
proliferation and possible tumorogenesis.  (Diabira and Morandi 2008). 
 Stem Cell Markers 
As introduced in Chapter 1, HSCs and their progeny are characterized by the 
array of cell surface antigens that they express.  Clonogenic pluripotent mouse HSCs and 
progenitor cells are contained within the CD 34
neg 
Sca-1 
pos
 CD45
neg
 c-kit
pos 
(CD117) 
lineage (Lin)
/low
 and Thy-1.1
low
(CD90) population of bone marrow (Ito, Li et al. 2003; 
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Abedi, Foster et al. 2007). It is suggested that this population of cells may represent 
universal pluripotent stem cells residing at different levels in multiple murine tissue cells 
(Grounds and Yablonka-Reuveni 1993). Lineage (Lin) markers are cell surface markers 
that mark differentiated peripheral blood cells (e.g. CD4-and CD8-). The marker, c-kit, or 
CD117, is another transmembrane glycoprotein and a member of the receptor tyrosine 
kinase subclass III family that is expressed on a number of cell types, including HSCs, 
mast cells, germ cells, and melanocytes (Wong, Lowes et al. 2007). It is important in the 
proliferation and
 
differentiation of hematopoietic cells and is coexpressed on 50–70% of 
CD34
+
, HSCs (Dooley, Oppenlander et al. 2004; Sharma, Cabana et al. 2008). Thy-1 
(CD-90) is a rather promiscuous molecule. It is expressed
 
by several different cell types, 
and, among others, it is present
 
on the surface of stem cells. It is expressed on 10–40% of 
CD34
+
 cells, the non-expressing population being HSCs (Christensen and Weissman 
2001; Wong, Lowes et al. 2007).    
Sca-1 in Muscle 
 In muscle, although 99% of quiescent satellite cells do not express Sca1, it is expressed 
in myogenic progenitor cells (MPCs) where it plays a role in regulating proliferation, cell 
cycle exit, differentiation, and fusion (Asakura, Seale et al. 2002). Primary MPCs 
heterogeneously express Sca-1 and those that are Sca-1 
pos
 divide slower and form 
myotubes
 
less readily than their Sca-1
neg
 counterparts (Mitchell, Mills et al. 2005). 
Blocking Sca-1
 
by antibodies or down regulating expression via antisense, inhibited MPC 
fusion and promoted proliferation. Therefore, in the absence of
 
Sca-1, proliferation and 
differentiation are favored at the expense of
 
self-renewal.  This has led to the proposal 
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that Sca-1 expressing MPCs represent “reserve cells” destined to return to quiescence 
thereby maintaining the satellite cell pool  (Zammit and Beauchamp 2001).
 
 
Other populations of cells expressing Sca-1 have been isolated from muscle 
tissue, leading to the hypothesis that there exists a more primitive stem cell population in 
muscle that gives rise to satellite cells, such that a stem cell hierarchy may also exist in 
muscle (Cossu and Biressi 2005). Polesskaya reported that CD45
pos
Sca-1 
pos
 muscle-
derived cells give rise to Pax7
pos 
myogenic cells in response to Wnt signaling during 
regeneration.
 
However, this has not been confirmed and it is generally accepted that 
CD45 is restricted to immuno-hematopoietic cells and is used to distinguish these cells 
from myogenic cells in muscle (Polesskaya, Seale et al. 2003; Sharma, Cabana et al. 
2008).  
 Endothelial cells found in the blood vessels of muscle readily express Sca-1 
(Tamaki, Akatsuka et al. 2002).  It is possible that they are a source of satellite cells as 
endothelial cells from the retina have been shown to activate early satellite cell markers 
and undergo myogenic differentiation when transplanted into muscle (Kirillova, Gussoni 
et al. 2007). Pericytes (mural cells), another type of cell from the vasculature system, may 
replenish the satellite cell pool when  satellite cells are depleted during injury or in 
neuromuscular degenerative disorders such as DMD (Dellavalle, Sampaolesi et al. 2007). 
Pericytes isolated from postnatal human skeletal muscle blood vessels can differentiate 
into muscle fibers in vitro and participate in muscle regeneration in vivo in host mice. 
The following are characteristics of pericytes compared to satellite cells: (1) they are 
located under the endothelium of small vessels, whereas satellite cells are located 
underneath the basal lamina of muscle fibers; (2) their growth requirements differ, 
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pericyte-derived cells undergo rapid senescence in cell culture media whereas satellite 
cells divide; (3) when placed in tissue culture under proliferation conditions, the 
pericytes-derived cells, unlike satellite cells do not express Pax7, MyoD or Myf5. Instead 
they express NG2 proteoglycan and alkaline phosphatase (ALP), both of which are not 
expressed in satellite cells. However, pericytes can undergo myogenic differentiation and 
express myogenic markers (MyoD and Myf5) (Dellavalle, Sampaolesi et al. 2007). 
Furthermore, pericyte-derived cells can cross the vessel wall, a feature presumed to be 
absent in satellite cell-derived myogenic progenitors, which make them potential 
candidates for cell therapy via systemic delivery to muscle (see Therapeutic Potential of 
Adult Stem Cells section, above) (Day, Shefer et al. 2007). 
 
Aging 
The most notable age-associated, functional change in HSCs, is  the decreased 
ability to home and engraft in  the bone marrow (Bordignon and Roncarolo 2002). This is 
true in rodents and humans; in a clinical setting increased donor age in bone marrow 
transplantation was found to be a predictor of transplant-related mortality. This suggests 
that the diminished reconstituting ability of HSCs from elderly donors is partly cell-
autonomous. These observations further suggest a clinically overt decrease in HSC 
functioning with normal human aging (Morrison, Wright et al. 1997). Detailed analysis 
of aging effects on HSCs in rodents is complicated by significant differences between 
strains. The HSCs of the C57BL/6 (B6) mice are only minimally
 
affected by aging 
because their numbers increase with age (de Haan and Van Zant 1999; Chen, Astle et al. 
2000; Sudo, Ema et al. 2000) and these cells can outlive their original
 
donor during serial 
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transplantation (Harrison 1979). In B6 mice, the homing properties
 
of HSCs are altered, 
reducing their ability to engraft recipients (Morrison, Wandycz et al. 1996; Liang, Van 
Zant et al. 2005). The progenitor cells from older B6 mice have a relatively low cycling 
activity, whereas the
 
stem cell pool increases with age and is relatively small (Kamminga 
and de Haan 2006).  
Compared to the B6 mice, aged DBA/2 (D2) mice have a shorter life span. An 
increased cycling activity is shown by their
 
progenitors and an apparent
 
exhaustion of the 
stem cell pool during maturation (de Haan, Nijhof et al. 1997). The stem
 
cell pool of D2 
mice decreases upon aging and is relatively large, which suggests that rapidly dividing 
cells exhaust faster than progenitor cells. Thus, the maximum life span of different inbred 
mouse strains negatively correlates with the percentage of progenitors in the S-phase
 
of 
the cell cycle (Roeder, Kamminga et al. 2005). The
 
genetic differences with respect to 
cycling activity and stem
 
cell pool population are still present when D2 and B6 cells co-
exist in
 
the same micro environment, suggesting these are cell intrinsic properties. In 
addition, differences
 
between the growth advantage of D2 and B6 stem cell  appear to be 
dependent on the actual state of the entire system and not a fixed cellular property(De 
Haan and Van Zant 1999). 
In muscle, the relative roles of the aging environment compared to age-associated 
inherent changes in satellite cell function are less clear cut. When young or aged muscle 
tissue is transplanted into a young host muscle bed, regeneration is excellent (Brack, 
Conboy et al. 2007). The opposite is observed in an aged host, which indicates that a 
systemic effect could be occurring. Similarly, when parabiotic pairs
 
of young and aged 
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mice sharing a common circulation are injured, the muscles
 
of the aged partner showed 
improved regenerative responses when parabiosed with a young mouse, whereas 
regeneration in the young animal is impaired (Schultz and Lipton 1982; Dodson and 
Allen 1987; Taylor-Jones, McGehee et al. 2002; Barani, Durieux et al. 2003; Gallegly, 
Turesky et al. 2004). 
 Work in vitro suggests that there are also intrinsic changes in MPC function that 
contribute to age dependent muscle loss (Lorenzon, Bandi et al. 2004; Conboy, Conboy 
et al. 2005; Fulle, Di Donna et al. 2005). Alterations in rodent MPC metabolic activity 
and proliferative capacity occur with age.  Further, changes in differentiation potential 
may contribute to intramyocellular lipid accumulation and muscle fibrosis, both 
processes regulated by Notch and Wnt signaling (Kida, Asahina et al. 2007; Brack, 
Conboy et al. 2008). The Wnt family of genes, encoding at least nineteen lipid modified 
signaling proteins, have been implicated in regulating proliferation and differentiation 
through the canonical -catenin and non-canonical pathways (for review see (Huelsken 
and Behrens 2002). Changes in Wnt 10b expression with age contribute to increased 
adipogenic potential of MPCs and overall Wnt/β catenin signaling increases in muscles 
as function of age (Vertino, Taylor-Jones et al. 2005) (Shimizu, Julius et al. 1997; 
Willert, Brown et al. 2003; Brack, Conboy et al. 2007). 
On the other hand, two recent studies (Shefer, Van de Mark et al. 2006; Collins, 
Zammit et al. 2007) show that satellite cell number is reduced with age, but the cells that 
remain retain proliferation and differentiation capacity. An age-dependent loss in cells 
destined for self-renewal from the satellite cell/MPC population would result in reduced 
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regenerative capacity. Based on this work, Dr. Peterson’s lab set out to test the hypothesis 
that Sca-1 expressing MPCs may be absent or depleted in aged muscle following injury.  
Immunohistochemical analysis of aged muscles suggested that Sca-1 expressing cells 
were actually increased in muscle with age and these cells appeared to lack myogenic 
potential (Hidestrand 2008 in press). The goal of my study was to quantify Sca-1 
expressing cells in muscle as a function of age and characterize them in vitro.  
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CHAPTER 3 
 
Experimental Materials and Methodology 
Animals 
 
Six months old (young adult) and 23-24 months old (aged) female DBA/2JNIA 
mice were obtained from the National Institute of Aging (NIA) Aged Rodent Colony at 
Harlan Sprague Dawley (Indianapolis, IN) and housed in the animal facility at the 
University of Kentucky (UK) with access to food and water. They were maintained on 
normal chow. All studies were approved by the University Animal Care and Use 
Committee and overseen by the Division of Laboratory Animal Resources (DLAR) at the 
University of Kentucky.   
 
Muscle – Derived Cell Isolation  
Cells were isolated from muscles of both hind limbs of 6 young adult and 6 aged 
DBA/2JNIA mice by enzymatic digestion. Bones and tendons were removed,
 
and the 
muscle tissue was thoroughly minced and then centrifuged for 2 minutes at a speed of 
800 x g and resuspended in DMEM (Dulbecco’s modified Eagle medium) (Invitrogen, 
Carlsbad, CA) with penicillin and streptomycin (p/s) (Invitrogen). The muscle was then 
digested for 30 minutes
 
at 37°C in 5% CO2 with 0.2% collagenase type II-filtered 
(Boehringer, Mannheim, Germany) which breaks down the native collagen to release 
cells, followed by 30 minutes in 0.5μ/mL of Dispase (Boehringer, Mannheim, Germany) 
a protease that is milder compared to collagenase. Following digestion, the cells were 
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pelleted by centrifugation for 3 minutes at 1000x g and resuspended in 10 ml of DMEM 
with 10 % fetal bovine serum (FBS, BioWhittaker, Walkerville, MD). The dissociated 
tissue
 
was triturated briefly by using a 25-mL pipette and was then passed sequentially
 
through 70-µm and 40 µm nylon mesh filters. Cells were counted manually using a 
hemocytometer (see detailed description below), which typically yielded 3 × 10
6
 to 
4 × 10
6
 cells/mouse before the filtrate was incubated at 37 
O
C in 5% CO2 for 6 hours. 
Cells were then centrifuged for 5 minutes at 900xg and resuspended in 1 ml of phosphate 
buffered saline (PBS). 
Cell Counting 
The hemacytometer counting chamber was used for counting cells on the inverted 
microscope at 10x and 40 x powers. It is constructed so that the distance between the 
bottom of the cover slip and the surface of the counting area of the chamber is 0.1mm. 
The surface of the chamber contains two square ruled areas separated by an H-shaped 
moat. These two squares are identical allowing the counter to duplicate the cell count. 
Approximately 20μL of   the total cells obtained in the above experiment was diluted in 
media (1:50 dilution). In a new tube 20μL of the dilution was added to 20μL of trypan 
blue (discussion below). Approximately 10μL of the solution was placed on the 
hemactyometer covered by a coverslip and counted using at least two quadrants. The 
following calculation below was used to determine the total amount of cells.  
 
Grp1: (______/2) * 100 * (10,000) = _______ cells/mL*___mL =      *multipy 
 All subsequent steps were performed on ice at 4 
O
C. Cells were counted for a 
second time using trypan blue. In a viable cell, trypan blue is excluded; however, it 
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traverses the membrane in a dead cell. Hence, dead cells are shown with a distinctive 
blue color under a microscope. The remaining cells were centrifugated for 5 minutes at 
600 x g and then resuspended in 100uL viral supernatant 2.4G2 (HB197, ATCC, 
Manassas, VA) at a concentration of 5x10
6
 cells/mL and incubated for 15 minutes in 
order to block nonspecific binding of the CD45 antibody.  After incubation the cells  
were centrifuged for 5 minutes at 600 x g and resuspended in 3mL of PF buffer (PBS 
with 0.5% FBS). 
Antibody Labeling  
 
The primary antibodies of CD45.2 conjugated with Allophycocyanin (APC)-
Alexa® Fluor750 and Sca-1, Ly-6A/E conjugated with Phycoerythrin (PE) were prepared 
and aliquoted in the following tubes: 
1. Control Tube 1 : 75 µL  of PF media only 
2. Control Tube 2: 75 µL  of PF  and 15 µL of  CD45: APC: AF (1:5 ) 
3. Control Tube 3: 75 µL  of PF  and 0.5µl Sca-1: PE(1:160) 
4. Sample Tube: 500µL of PF including 100µL CD45: APC-AF (1:5) and 3.125 
µLSca-1: PE (1:160).  The cells sample volume aliquot for all controls was 
determined by the following standard calculation : 
(0.5 X10
6
) * (total volume/total cell count) (* multiply). 
Antibody CD45.2 is commonly used for the following mouse strains C57BL/6, BALB/c, 
DBA/1, and DBA/2. It is a 104 clone monoclonal antibody, which reacts with the mouse 
CD45 molecule. The conjugation with the fluorescent dye (APC)-Alexa® Fluor 750 
produces photo-emission properties and compensation, which includes the peak emission 
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of 779 nm, a slightly higher mean fluorescent intensity and a more photo stable 
fluorochrome when compared to the similar clone conjugated antibodies. The Sca-1Ly-
6A/E antibody is also commonly used in similar mouse strains previously listed above. It 
is a monoclonal antibody that reacts with both Sca-1Ly-6A.2 and Ly-6E.1 molecules. The 
conjugation of Sca-1Ly-6A/E antibody with phycoerythrin (PE), one of the most 
commonly-used fluorescent dyes for FACS analysis (see detailed discussion below) 
produces a huge absorption coefficient and almost perfect quantum efficiency. It emits at 
about 570 nm, one of the brightest dyes used today. However, it is sensitive to photo-
induced oxidation; therefore, the dye and samples containing the dye must always be 
protected from light.  
 In order to determine the final volume of cells to be used for FACS analysis, a 
final count was done (the number of cells must be ≥  1.0x107mL), which yielded 
approximately 1.2x10
7
 and 2.1x10
7
 cells for the aged for the adult mice respectively. 
Cells were added to the  four tubes described above and centrifuged for 4 minutes at 600 
x g and resuspended in 0.5mL of PF buffer (process was repeated twice). Eppendorf 
collection tubes were prepared to collect samples after they were sorted. Immediately 
before the samples were subjected to FACS, a 1:3 dilution of propidium iodine (PI) in 
PBS was made and added to the tube. PI is commonly used for identifying dead cells in a 
population of cells and also acts as a counter stain in multicolor fluorescent techniques. 
Finally, due to the viscosity of the labeled cells, they are filtered through a 30 µm filter 
and then approximately 2-4 mL were subjected to FACS analysis on a BD Biosciences 
FACS Vantage cell sorter. The aim was to collect Sca-1 positive and negative cells 
isolated from the CD45 negative pool, which were then cultured for 
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immunocytochemistry and/or for RNA isolation.  The entire FACS analysis was repeated 
on both groups of 6 young adult and 6 aged mice twice. 
Flow Cytometry for FACS Analysis 
Since its inception more than 30 years ago flow cytometry has become an 
essential tool for both researchers and clinicians. This technique is used for counting, 
examining, and sorting microscopic particles suspended in a stream of fluid (Longobardi 
2001). It allows simultaneous multiparametric analysis of the physical and/or chemical 
characteristics of single cells flowing through an optical and/or electronic detection 
apparatus. A flow cytometer is similar to a microscope, except that instead of producing 
an image of the cell, flow cytometry offers high-throughput (for a large number of cells) 
automated quantification of set parameters (Shapiro 2003).  Fluorescence-activated cell 
sorting/sorter (FACS) is a specialized type of flow cytometry. It provides a method for 
sorting a heterogeneous mixture of biological cells into two or more containers, one cell 
at a time, based upon the specific light scattering and fluorescent characteristics of each 
cell. It provides fast, objective and quantitative recording of fluorescent signals from 
individual cells as well as physical separation of cells of particular interest (Longobardi 
2001).As the fluid containing the cells, which is entrained in the center, passes through a 
narrow orifice (~100µm in diameter) into the air, a beam of light (usually laser light) of a 
specific wavelength is directed onto this hydro-dynamically focused stream of fluid 
(Wiley-Liss 2007). At the same time, the flow chamber is vibrated by the attached 
piezoelectric crystal, at frequencies approximating 20,000Hz. The vibration produces a 
disturbance in the ejected stream. The disturbance grows very rapidly and the stream 
eventually breaks into individual droplets (20,000 drops per second)(Wiley-Liss 2007). 
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The steady vibration causes the drops to be uniform in size and spacing. Each cell that 
flows through the system will end up in a drop. A number of detectors are aimed at the 
point where the stream passes through the laser light beam; one in line or approximately 
2
0
-20
0
 with the light beam (Forward Scatter or FSC), several perpendicular or 90
0
 to it 
(Side Scatter or SSC) and one or more fluorescent detectors  (Shapiro 2003). 
Each suspended particle passing through the beam scatters the light in some way, 
and fluorescent chemicals found in the particle or attached to the particle may be excited 
into emitting light at a lower frequency than the light source. This combination of 
scattered and fluorescent light is picked up by the detectors, and by analyzing fluctuations 
in brightness at each detector (one for each fluorescent emission peak) it is then possible 
to extrapolate various types of information about physical and chemical structure of each 
individual particle. FSC correlates with the cell volume and size of the cell. It is also 
more sensitive to surface properties of particles (cell ruffling) and will distinguish live 
from dead cells. SSC depends on the inner complexity of the particle (i.e. shape of the 
nucleus, the amount and type of cytoplasmic granules or the membrane roughness) 
(Wiley-Liss 2007). 
Finally, if the measurement result indicates that the cell is to be sorted, a voltage 
is applied to the stream and a droplet begins to form. When the drop separates from the 
stream it will carry an electric charge. The voltage on the stream is immediately reduced 
to zero so that other drops will not be charged. Charges can be negative or positive, 
enabling the sorting of two categories of cells simultaneously. As the drop continues to 
move downward, they pass between two metal plates charged to a high voltage. The 
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drops now contain the selected charged cells and because of this they are deflected from 
the main stream of drops and collected in eppendorf tubes for visual examination or 
cultured for RNA isolation. Drops containing undesired cells are not charged and go 
directly into a waste tube (Shapiro 2003). 
RNA Isolation 
Following FACS, Sca-1 labeled (Sca-1
pos
) and unlabeled (Sca-1
neg
) cells from the 
CD45 negative population were expanded on collagen-coated plates (Sigma, St. Louis, 
MO) and maintained in growth medium containing Ham’s F-10 (BioWhittaker) 
supplemented with 20% FBS, 0.5% pen-strep and 5 ng/mL basic fibroblast growth factor  
(bFGF, Promega, Madison, WI) at 37 C in a humidified 5% CO2-95% air atmosphere.  
To assess myogenic potential, cells were grown to confluence and then switched to 
differentiation medium consisting of DMEM with 2% horse serum (Hyclone, Logan, UT) 
and 0.5% pen-strep. Total RNA was prepared from primary cultures using the RNAqeous 
4PCR kit (Ambion, Austin, TX) including DNAse treatment technique, according to the 
manufacturer’s recommendations.  This kit disrupts cells in a solution containing 
guanidinium thiocyanate (lysis binding solution), a strong chaotropic denaturant which 
lyses cell membranes and rapidly inactivates cellular ribonucleases (Chirgwin, Przybyla 
et al. 1979; Chomczynski and Sacchi 1987). Approximately 10
5
 cells were disrupted by 
the addition of lysis binding solution and then transferred to a tube and vortexed to ensure 
complete cellular disruption. The lysate was then mixed with an ethanol solution, and 
applied to a silica-based filter which selectively binds mRNA and the larger ribosomal 
RNAs; however, very small RNAs such as tRNA and 5S ribosomal RNA are not bound. 
The filter was washed to remove residual DNA, protein, and other contaminants, and the 
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RNA was eluted in nuclease-free water containing a trace amount of EDTA to chelate 
heavy metals. The silica filter is housed in a small cartridge which fits into the RNase-
free microfuge tubes supplied with the kit. The sample lysate, wash solutions, and elution 
solution are permeated through the filter by centrifugation or vacuum pressure. The entire 
RNA isolation procedure takes about 10 minutes. After elution from the filter, the RNA 
was treated with the ultra-pure DNase 1 solution provided with the kit by the manufacture 
to remove trace amounts of DNA. Finally, the DNase was inactivated and divalent 
cations removed. DNase treatment and inactivation takes about 30 minutes. This 
treatment is critical in the RT-PCR technique because no RNA isolation procedure can 
guarantee the complete removal of trace amounts of DNA below the limit of detection by 
RT-PCR. It is especially important that no DNA is present in RT-PCRs using primers 
that do not flank introns, or for genes that have processed pseudogenes, because the RT-
PCR products from RNA and contaminating DNA cannot be distinguished by size in 
these cases. The DNase I solution was removed because it could degrade DNA made in 
the PCR. The DNase Inactivation Reagent is also used to remove divalent cations 
introduced by the DNase 1 Buffer. The quality of RNA was assessed with a Bioanalyzer 
nanochip assay (Agilent Technologies, Santa Clara, CA) and RNA concentration was 
determined with a spectrophotometer by measuring the absorbance at 260 nm.  
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Real time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
RNA was analyzed using RT-PCR, the most sensitive technique for mRNA 
quantification that is routinely used. The technique is sensitive enough to enable 
quantitation of RNA from a single cell. Gene expression was quantified by real-time RT-
PCR utilizing a standard curve from pooled cDNAs on an IQ5 icycler using SYBRGreen 
(BioRad, Hercules, CA). For these experiments 1 µg of RNA was converted to cDNA 
using the iScript reverse transcriptase kit (BioRad). Depending on the gene being 
analyzed 0.1-10 ng of cDNA/well was used for real-time analysis. In all cases the primer 
concentrations were held at 0.3µM and the annealing temperature was set at 60°C. 
Reactions were characterized by a single peak melting curve, 90-110% amplification 
efficiency of the standard curve, and no amplification of a non- template control. Samples 
were run in duplicate and experiments repeated 3 times. Each value was normalized to 
18s ribosomal RNA using 18s F primer 5'- AATGAGCCATTCGCAGTTTC -3' and R 
primer 5'- CTCTGTTCCGCCTAGTCCTG -3'. All other primer sequences can be found 
at http://pga.mgh.harvard.edu/primerbank/ using the following Genbank accession 
numbers: Cyclin D1, NM_007631; CyclinD2, NM_009829; Myc, NM_010849; Wnt2, 
NM_023653; Wnt7b, NM_009528; Wnt10, NM_011718; Twist1, NM_011658; 
Fibronectin, AF095690; CTGF, NM_010217.  Results were analyzed using two–way 
Analysis of Variance (ANOVA) and are presented as means and standard deviations. 
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CHAPTER 4 
Results 
 
Quantification of Sca-1 expressing (Sca-1 pos) cells from adult and aged mice muscle 
 
Immunohistochemical analysis of mice hind limb muscles showed that Sca-1 
expressing cells increased in abundance with age(Hidestrand 2008 in press). To quantify 
the cells and characterize them in detail, hind limb muscles of adult (6 months old n= 6) 
and aged (23-24 months old, n= 6) female mice were enzymatically digested and 
mononucleated cells isolated. The muscle derived cells were counted (three times) at 
different stages throughout the experiment manually with a hemocytometer prior to 
Fluorescent Activating Cell Sorting (FACS). Table 1 show that muscles from the adult 
mice yielded a larger number (43.5 x10
6
) of cells overall compared to the aged muscles 
(23x10
6
). However, significant cell loss was noted in both age groups during further 
processing such that  cell number dropped by approximately half (11.5 x10
6
 cells from 
aged mice
 
and 21.0 x10
6 
cells  from 
 
adult). Finally, the cells yielded by both groups of 
mice are consistent with published data, which suggest that a typical yield of cells for two 
hind limbs from a mouse ranged between 3 x10
7
- 4x10
7
. 
 
Table 1: Summary of cells counted manually by hemocytometer prior to FACS Analysis 
 
Type of mice Count  1 Count 2 Count 3 
Aged 2.3 x10
7
 1.2 x10
7
 1.2 x10
7
 
Adult  4.4x10
7
 2.2 x10
7
 2.2 x10
7
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 Figure1A. 
 
Figure1B. 
 
Figure1C. 
Figure1: Fluorescent Activating Cell Sorting (FACS) parameters for CD45neg cells. 
The above figures illustrate a   profile of all cells to be sorted based on size (FSC) and 
granularity (SSC) (A). The viable cell population (Region 1 in B) enriched for non- 
hematopoietic stem cells (CD45 negative, R5 in C) was selected using propidium iodine. 
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To identify Sca-1 
pos
 cells derived specifically from muscle progenitors cells (MPCs), an 
antibody to CD45 was used to select against immuno-hematopoietic cells (CD45
pos
). 
Several other cell parameters were also quantified during sorting (Figure 1). The forward 
scatter (FSC)on the x axis versus the side scatter (SSC) on the y axis  in Figure 1A 
displays the profile for all cells collected based on their surface properties which includes 
size and granularity respectively. In Figure 1B the forward scatter versus propidium 
iodine (PI) allows for selection of viable cells (R1) excluding fragments (located on the 
far left), aggregates (located on far right) and nonviable cells (PI 
pos
). Finally, the 
histogram shown in Figure 1C is a representation of the CD45 negative cell population 
(R5) that was further sorted based on Sca-1 cell surface expression. 
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Figure 2A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FF  
 
 
 
 
F 
Figure 2B  
Figure 2: FACS profile of CD45 and Sca-1 expressing and non-expressing cells in  
                 muscle from adult and aged mice 
 
 CD45 versus Sca-1 cells demonstrates an increased abundance of CD45
neg
Sca-1
pos 
cells 
in muscle from aged (A) compared to adult (B) mice. 
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Sorting gates of the viable cells (R1, Figure 1B) were used to identify CD45
neg 
Sca-1
pos 
cells from adult and aged mice. In this representative analysis, repeated twice, 14.2% of 
the cells from aged mice were CD45
neg 
and Sca-1
pos
 (Figure 2A),
 
while 7.2% of similar 
cells were observed in the adult mice ((Figure 2B). These results show that although total 
cell number decreases as a function of age, Sca-1expressing non-immuno-hematopoietic 
cells are twice as abundant in aged compared to young adult muscle.  
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Figure 3A 
 
 
 
Figure 3B
 
 
Figure 3: In vitro characterization of Sca-1 pos and Sca-1 neg cells from aged and 
                young adult muscle in culture. 
 
 Sca-1 
pos
 (A) and Sca-1 
neg
 (3B) cells from aged muscle in culture for approximately 2 
weeks. 
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Previous results from Dr. Peterson’s laboratory showed that although Sca-1 expressing 
cells in aged muscle were derived from MPCs, they lacked myogenic potential. Sca-1 
pos
 
cells from aged muscle did not express myogenic genes such as MyoD, and did not fuse 
or differentiate into myotubes (Hidestrand 2008 in press).To further characterize   the  
Sca-1  expressing cells from aged muscle, the FACS isolated Sca-1
pos
 and Sca-1 
neg
 cells, 
were expanded in culture. After approximately two weeks in culture, Sca-1
pos
 cells were 
quite large and flattened (Figure 3A) compared to Sca-1 
neg 
cells (Figure 3B). The 
morphology of the Sca-1 
neg 
cells was typical of normal MPCs. They readily differentiate 
in low serum- containing differentiation media; whereas the FACS sorted Sca-1
pos
 cells 
did not fuse to form myotubes.  
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Figure 4A      Figure 4B                   Figure 4C    
 
 
 
 
 
 
Figure 4D    Figure 4E                 Figure 4F    
 
 
 
 
 
 
Figure 4G    Figure 4H                  Figure 4I   
Figure 4: Gene expression analysis of Sca-1 pos cells compared to Sca-1 neg MPCs from   
                 adult and aged muscle. 
 
mRNA abundance for the indicated genes was quantified by real time RT-PCR. The data 
were analyzed by two-way Analysis of Variance (ANOVA) and expressed as different 
from aged mice (p<0.05 is as * and p<0.005 is assigned as **). 
 
Wnt2/18s
adult aged Sca-1+
A
U
0
13
25
38
50 **
Myc/18s
adult aged Sca-1+
A
U
0.0
0.5
1.0
1.5
2.0 *
Twist1/18s
adult aged Sca-1+
A
U
0
4
8
12
16 **
Wnt7B/18s
adult aged Sca-1+
A
U
0.0
0.6
1.2
1.8
2.4
*
**
CyclinD1/18s
adult aged Sca-1+
A
U
0
1
2
3
4 **
CTGF/18s
adult aged Sca-1+
A
U
0
2
4
6
8
**
Wnt10b/18s
adult aged Sca-1+
A
U
0.00
0.05
0.10
0.15
**
CyclinD2/18s
adult aged Sca-1+
A
U
0
2
4
6
**
Fibronectin/18s
adult aged Sca-1+
A
U
0
2
4
6 **
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 To characterize the cells further, RNA was isolated from Sca-1 
neg
 adult (6 
months-old) and aged (23-24 months-old) MPCs and from FACS isolated CD45
neg 
Sca-
1
pos
 cells from 23-24 months-old mice (stable populations of Sca-1
pos
 cells from young 
animals were not available due to the dynamic expression of Sca-1 in these cells) and   
analyzed by real time reverse transcriptase PCR (Figure 4). The data presented in Figure 
4 represent the means and standard deviations normalized to 18s, expressed as arbitrary 
units (AU). The following specific Wnt genes (Wnt2, 7b and 10b,) showed the greatest 
difference in gene expression between the cell types. Wnt2 (Figure 4A) was dramatically 
over expressed in Sca-1
pos
 cells which was associated with over expression of 
downstream target genes of canonical Wnt signaling such as c-myc (Figure 4B) and 
cyclins D1 and D2 (Figure 4E and 4H, respectively). Wnt7b mRNA (Figure 4D) was 
expressed at lower levels in both cell types from aged mice relative to young adult MPCs, 
potentially contributing to decrease myogenic potential in both cell types from aged mice. 
The Wnt10b gene (Figure 4G), that has been implicated in regulating adipogenesis was 
down regulated only in aged MPCs.  Genes involved in fibrosis such as Twist (Figure 
4C) connective tissue growth factor (CTGF, Figure 4F) and fibronectin (Figure 4I) were 
significantly over expressed in Sca-1
pos
 cells compared to MPCs. 
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CHAPTER 5 
 
Discussion and Conclusion 
Stem cell antigen-1(Sca-1) is expressed
 
by stem, progenitor, and differentiated 
cell types
 
in a wide variety of tissues and organs (Bamezai 2004; Holmes and Stanford 
2007). In muscle, it has been proposed to play a role in controlling normal muscle 
satellite cell/MPC function (Fukada, Uezumi et al. 2007). However, these experiments 
have identified a subpopulation of cells (CD45
neg
Sca-1
pos
) that increase in abundance 
with age (Figure 2). This unique subpopulation of cells has an altered differentiation 
potential.  
Quiescent satellite cells in young muscle do not express Sca-1 and give rise to 
MPCs that are heterogeneous for Sca-1 expression (Asakura, Seale et al. 2002). It has 
been proposed that Sca-1 may identify MPCs destined to return to the satellite cell pool 
(Mitchell, Mills et al. 2005). In aged muscle, cells expressing Sca-1 do not possess 
myogenic potential and may be  undergoing apoptosis resulting in depletion of the stem 
cell pool in vivo (Hidestrand 2008 in press).However, not all cells are lost, and those that 
remain do not express myogenic markers and instead may contribute to muscle fibrosis 
with age, potentially controlled by Wnt signaling with β catenin as the integral 
component  of the system (Willert, Brown et al. 2003; Brack, Conboy et al. 2007). Wnts 
are a major class of secreted morphogenic ligands with a role in generation, maintenance 
and /or differentiation of early progenitor cells in all multicellular organisms (Huelsken 
and Behrens 2002). They play a very important role in regulating ostegenesis, 
adipogenesis and myogenesis in adult tissues, subsequently controlling the fate of the 
resident stem cells (Lako, Lindsay et al. 2001; Vertino, Taylor-Jones et al. 2005). In the 
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absence of Wnt signaling,
 β-catenin is phosphorylated by glycogen synthase kinase 
(GSK),
 
leading to rapid degradation. The ligands of Wnt bind
 
to transmembrane receptors 
of the Frizzled family, leading to
 
inactivation of GSK within the complex, thereby 
stabilizing
 β-catenin, allowing translocation to the nucleus where it regulates T-cell factor 
/leukocyte enhancing factor-dependent (TCF/LEF) gene
 
transcription(Willert and Nusse 
1998). Recent studies have shown that Wnts have distinct effects
 
during limb myogenic 
differentiation (Van Den Berg, Sharma et al. 1998; Lako, Lindsay et al. 2001; Fevr, 
Robine et al. 2007).  However, in contrast, Wnt signaling seems to inhibit adipogenic 
differentiation (Shimizu, Julius et al. 1997; Ross, Hemati et al. 2000; Bennett, Ross et al. 
2002; Vertino, Taylor-Jones et al. 2005; Brack, Conboy et al. 2007; Fevr, Robine et al. 
2007).  
 Due to these important roles of the Wnt signaling pathway it prompted us to 
examine this class of genes in Sca-1
pos
cells. In our study, we found that Wnt7b, which 
promotes myogenic differentiation (Vertino, Taylor-Jones et al. 2005), is down regulated 
in both aged Sca-1
neg
 and Sca-1
pos
 cells, which may contribute to impaired myogenic 
potential of both cell populations.Wnt10b, which inhibits adipogenic differentiation 
(Ross, Hemati et al. 2000; Bennett, Ross et al. 2002), declines only in aged MPCs, 
potentially accounting for increased adipogenic potential specifically in those cells. As 
overall markers of Wnt/β-catenin signaling, myc and cylins D1 and D2 appear to be up-
regulated in the Sca-1
pos
 cells, Wnt7b and 10b likely signal through non-canonical 
pathways to control differentiation potential.   
Wnt2 (Figure 4A) was highly over expressed in Sca-1
pos
 cells that may be 
responsible for increased expression of the down stream targets of canonical Wnt/β-
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catenin signaling (Brack, Conboy et al. 2007). Moreover, genes associated with fibrosis, 
including Twist1 (Figure 4C), CTGF (Figure 4F), and fibronectin (Figure 4I) are over 
expressed in Sca-1
pos
 cells compared to both young adult and aged Sca-1
neg 
MPCs. In the 
kidney Wnt 2 is associated with fibrosis and directly regulates Twist 1 gene expression 
(Kida, Asahina et al. 2007).Twist also inhibits MyoD function which contributes to 
impaired myogenic potential (Hamamori, Wu et al. 1997). These results are consistent 
with a recent study done by Brack et. al which also shows that following injury in aged 
muscle, satellite cells/MPCs may contribute to fibrosis which is associated with increased 
canonical Wnt signaling. The data obtained from our experiments suggest that Sca-1 is a 
useful marker of this transition from myogenic to fibrogenic potential during 
aging.(Brack, Conboy et al. 2007). The fact that age-dependent differences in phenotype 
are stable in culture suggests that inherent changes in cell potential occur. However, 
satellite cell and MPC function are also clearly influenced by the aged muscle 
environment(Carlson and Faulkner 1989; Conboy, Conboy et al. 2003; Conboy, Conboy 
et al. 2005; Rando 2006). 
 
The majority of the work presented and discussed in this paper is on mice; 
however, interesting parallels appears to exist with humans muscle progenitor cells. 
Presently, a human homolog is not yet identified, however, researchers  analyzing Sca-1 
mutant mice have demonstrated the following important stem cell concepts that are 
equally relevant to human health and disease: the importance of mesenchymal stem and 
progenitor cells to bone homeostasis and deterioration, the association between 
degenerative diseases and exhaustion of the stem cell pool, and the importance of the 
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stem cell stress responses to tissue maintenance (Holmes and Stanford 2007). Therefore, 
further experiments are required to determine if modulation of Sca-1 expression may alter 
the properties of the satellite cells/MPCs and lead to long-term consequences for muscle 
growth. 
 
Finally, due to the growing demand for regenerative medicine, understanding the 
basic biological properties of mammalian stem cells, including Sca-1 is of paramount 
importance. This could offer hope for the treatment of many devastating degenerative 
diseases such as diabetes, Parkinson's disease, and Alzheimer's disease and muscular 
degenerative diseases such as Duchenne muscular dystrophy (DMD) and muscle atrophy 
during aging (sacropenia). 
 
 
 
 
 
 
 
 
 
 
 
 
 45 
 
REFERENCES 
Abedi, M., B. M. Foster, et al. (2007). "Haematopoietic stem cells participate in muscle 
regeneration." Br J Haematol 138(6): 792-801. 
Akashi, K., D. Traver, et al. (2000). "A clonogenic common myeloid progenitor that 
gives rise to all myeloid lineages." Nature 404(6774): 193-7. 
Asakura, A., P. Seale, et al. (2002). "Myogenic specification of side population cells in 
skeletal muscle." J Cell Biol 159(1): 123-34. 
Bamezai, A. (2004). "Mouse Ly-6 proteins and their extended family: markers of cell 
differentiation and regulators of cell signaling." Arch Immunol Ther Exp (Warsz) 
52(4): 255-66. 
Barani, A. E., A. C. Durieux, et al. (2003). "Age-related changes in the mitotic and 
metabolic characteristics of muscle-derived cells." J Appl Physiol 95(5): 2089-98. 
Barford, D., A. J. Flint, et al. (1994). "Crystal structure of human protein tyrosine 
phosphatase 1B." Science 263(5152): 1397-404. 
Baumheter, S., M. S. Singer, et al. (1993). "Binding of L-selectin to the vascular 
sialomucin CD34." Science 262(5132): 436-8. 
Becker, A. J., C. E. Mc, et al. (1963). "Cytological demonstration of the clonal nature of 
spleen colonies derived from transplanted mouse marrow cells." Nature 197: 452-
4. 
Beghe, C., A. Wilson, et al. (2004). "Prevalence and outcomes of anemia in geriatrics: a 
systematic review of the literature." Am J Med 116 Suppl 7A: 3S-10S. 
Bellantuono, I. and W. N. Keith (2007). "Stem cell ageing: does it happen and can we 
intervene?" Expert Rev Mol Med 9(31): 1-20. 
Bennett, C. N., S. E. Ross, et al. (2002). "Regulation of Wnt signaling during 
adipogenesis." J Biol Chem 277(34): 30998-1004. 
Bischoff, R. and C. Heintz (1994). "Enhancement of skeletal muscle regeneration." Dev 
Dyn 201(1): 41-54. 
Blau, H. M. and C. Webster (1981). "Isolation and characterization of human muscle 
cells." Proc Natl Acad Sci U S A 78(9): 5623-7. 
Blau, H. M., C. Webster, et al. (1983). "Defective myoblasts identified in Duchenne 
muscular dystrophy." Proc Natl Acad Sci U S A 80(15): 4856-60. 
Bodine-Fowler, S. (1994). "Skeletal muscle regeneration after injury: an overview." J 
Voice 8(1): 53-62. 
Bonaros, N., R. Rauf, et al. (2007). "Neoangiogenesis after combined transplantation of 
skeletal myoblasts and angiopoietic progenitors leads to increased cell 
engraftment and lower apoptosis rates in ischemic heart failure." Interact 
Cardiovasc Thorac Surg. 
Bordignon, C. and M. G. Roncarolo (2002). "Therapeutic applications for hematopoietic 
stem cell gene transfer." Nat Immunol 3(4): 318-21. 
Brack, A. S., I. M. Conboy, et al. (2008). "A temporal switch from notch to wnt signaling 
in muscle stem cells is necessary for normal adult myogenesis." Cell Stem Cell 
2(1): 50-9. 
Brack, A. S., M. J. Conboy, et al. (2007). "Increased Wnt signaling during aging alters 
muscle stem cell fate and increases fibrosis." Science 317(5839): 807-10. 
 46 
 
Bradfute, S. B., T. A. Graubert, et al. (2005). "Roles of Sca-1 in hematopoietic 
stem/progenitor cell function." Exp Hematol 33(7): 836-43. 
Brooke, M. H. and W. K. Engel (1969). "The histographic analysis of human muscle 
biopsies with regard to fiber types. 4. Children's biopsies." Neurology 19(6): 591-
605. 
Cardasis, C. A. and G. W. Cooper (1975). "An analysis of nuclear numbers in individual 
muscle fibers during differentiation and growth: a satellite cell-muscle fiber 
growth unit." J Exp Zool 191(3): 347-58. 
Carlson, B. M. and J. A. Faulkner (1989). "Muscle transplantation between young and 
old rats: age of host determines recovery." Am J Physiol 256(6 Pt 1): C1262-6. 
Cartee, G. D. (1995). "What insights into age-related changes in skeletal muscle are 
provided by animal models?" J Gerontol A Biol Sci Med Sci 50 Spec No: 137-41. 
Chambers, S. M., C. A. Shaw, et al. (2007). "Aging hematopoietic stem cells decline in 
function and exhibit epigenetic dysregulation." PLoS Biol 5(8): e201. 
Chen, J., C. M. Astle, et al. (2000). "Genetic regulation of primitive hematopoietic stem 
cell senescence." Exp Hematol 28(4): 442-50. 
Cheng, T. (2008). "Toward 'SMART' stem cells." Gene Ther 15(2): 67-73. 
Chirgwin, J. M., A. E. Przybyla, et al. (1979). "Isolation of biologically active ribonucleic 
acid from sources enriched in ribonuclease." Biochemistry 18(24): 5294-9. 
Chomczynski, P. and N. Sacchi (1987). "Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction." Anal Biochem 162(1): 
156-9. 
Christensen, J. L. and I. L. Weissman (2001). "Flk-2 is a marker in hematopoietic stem 
cell differentiation: a simple method to isolate long-term stem cells." Proc Natl 
Acad Sci U S A 98(25): 14541-6. 
Civin, C. I., L. C. Strauss, et al. (1984). "Antigenic analysis of hematopoiesis. III. A 
hematopoietic progenitor cell surface antigen defined by a monoclonal antibody 
raised against KG-1a cells." J Immunol 133(1): 157-65. 
Collins, C. A., P. S. Zammit, et al. (2007). "A population of myogenic stem cells that 
survives skeletal muscle aging." Stem Cells 25(4): 885-94. 
Conboy, I. M., M. J. Conboy, et al. (2003). "Notch-mediated restoration of regenerative 
potential to aged muscle." Science 302(5650): 1575-7. 
Conboy, I. M., M. J. Conboy, et al. (2005). "Rejuvenation of aged progenitor cells by 
exposure to a young systemic environment." Nature 433(7027): 760-4. 
Cooper, R. N., S. Tajbakhsh, et al. (1999). "In vivo satellite cell activation via Myf5 and 
MyoD in regenerating mouse skeletal muscle." J Cell Sci 112 ( Pt 17): 2895-901. 
Cossu, G. and S. Biressi (2005). "Satellite cells, myoblasts and other occasional 
myogenic progenitors: possible origin, phenotypic features and role in muscle 
regeneration." Semin Cell Dev Biol 16(4-5): 623-31. 
Dalton, S. (2008). "Cardiac stem cells: at the heart of cell therapy." Regen Med 3(2): 181-
8. 
Day, K., G. Shefer, et al. (2007). "Nestin-GFP reporter expression defines the quiescent 
state of skeletal muscle satellite cells." Dev Biol 304(1): 246-59. 
de Haan, G., W. Nijhof, et al. (1997). "Mouse strain-dependent changes in frequency and 
proliferation of hematopoietic stem cells during aging: correlation between 
lifespan and cycling activity." Blood 89(5): 1543-50. 
 47 
 
de Haan, G. and G. Van Zant (1999). "Dynamic changes in mouse hematopoietic stem 
cell numbers during aging." Blood 93(10): 3294-301. 
De Haan, G. and G. Van Zant (1999). "Genetic analysis of hemopoietic cell cycling in 
mice suggests its involvement in organismal life span." FASEB J 13(6): 707-13. 
Dellavalle, A., M. Sampaolesi, et al. (2007). "Pericytes of human skeletal muscle are 
myogenic precursors distinct from satellite cells." Nat Cell Biol 9(3): 255-67. 
Diabira, S. and X. Morandi (2008). "Gliomagenesis and neural stem cells: Key role of 
hypoxia and concept of tumor "neo-niche"." Med Hypotheses 70(1): 96-104. 
Dodson, M. V. and R. E. Allen (1987). "Interaction of multiplication stimulating 
activity/rat insulin-like growth factor II with skeletal muscle satellite cells during 
aging." Mech Ageing Dev 39(2): 121-8. 
Dooley, D. C., B. K. Oppenlander, et al. (2004). "Analysis of primitive CD34- and 
CD34+ hematopoietic cells from adults: gain and loss of CD34 antigen by 
undifferentiated cells are closely linked to proliferative status in culture." Stem 
Cells 22(4): 556-69. 
Druker, B. J. (2002). "Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy 
for CML." Oncogene 21(56): 8541-6. 
Edstrom, E. and B. Ulfhake (2005). "Sarcopenia is not due to lack of regenerative drive 
in senescent skeletal muscle." Aging Cell 4(2): 65-77. 
F. P. Moss, C. P. L. (2005). "Satellite cells as the source of nuclei in muscles of growing 
rats "  170(4): 421-435. 
Fevr, T., S. Robine, et al. (2007). "Wnt/beta-catenin is essential for intestinal homeostasis 
and maintenance of intestinal stem cells." Mol Cell Biol 27(21): 7551-9. 
Fina, L., H. V. Molgaard, et al. (1990). "Expression of the CD34 gene in vascular 
endothelial cells." Blood 75(12): 2417-26. 
Fukada, S., A. Uezumi, et al. (2007). "Molecular signature of quiescent satellite cells in 
adult skeletal muscle." Stem Cells 25(10): 2448-59. 
Fulle, S., S. Di Donna, et al. (2005). "Age-dependent imbalance of the antioxidative 
system in human satellite cells." Exp Gerontol 40(3): 189-97. 
Fuller, J. (2006). "Stem cell aging and cancer." Sci Aging Knowledge Environ 2006(9): 
pe12. 
Gallegly, J. C., N. A. Turesky, et al. (2004). "Satellite cell regulation of muscle mass is 
altered at old age." J Appl Physiol 97(3): 1082-90. 
Gluckman, E. and F. Locatelli (2000). "Umbilical cord blood transplants." Curr Opin 
Hematol 7(6): 353-7. 
Goodell, M. A., K. Brose, et al. (1996). "Isolation and functional properties of murine 
hematopoietic stem cells that are replicating in vivo." J Exp Med 183(4): 1797-
806. 
Grounds, M. D. and Z. Yablonka-Reuveni (1993). "Molecular and cell biology of skeletal 
muscle regeneration." Mol Cell Biol Hum Dis Ser 3: 210-56. 
Gumley, T. P., I. F. McKenzie, et al. (1995). "Tissue expression, structure and function of 
the murine Ly-6 family of molecules." Immunol Cell Biol 73(4): 277-96. 
Guralnik, J. M., R. S. Eisenstaedt, et al. (2004). "Prevalence of anemia in persons 65 
years and older in the United States: evidence for a high rate of unexplained 
anemia." Blood 104(8): 2263-8. 
 48 
 
Gussoni, E., Y. Soneoka, et al. (1999). "Dystrophin expression in the mdx mouse restored 
by stem cell transplantation." Nature 401(6751): 390-4. 
Hamamori, Y., H. Y. Wu, et al. (1997). "The basic domain of myogenic basic helix-loop-
helix (bHLH) proteins is the novel target for direct inhibition by another bHLH 
protein, Twist." Mol Cell Biol 17(11): 6563-73. 
Harrison, D. E. (1979). "Mouse erythropoietic stem cell lines function normally 100 
months: loss related to number of transplantations." Mech Ageing Dev 9(5-6): 
427-33. 
Harrison, D. E., C. M. Astle, et al. (1989). "Numbers and functions of transplantable 
primitive immunohematopoietic stem cells. Effects of age." J Immunol 142(11): 
3833-40. 
Hidestrand  M, Richards-Malcolm S., Gurley  C.M, Nolen G,  Grimes B,  Van  Zant  G, 
Peterson C.A (2008). "Sca-1 expressing non-myogenic cells contribute to fibrosis 
in aged skeletal muscle." 
Hofmeister, C. C., J. Zhang, et al. (2007). "Ex vivo expansion of umbilical cord blood 
stem cells for transplantation: growing knowledge from the hematopoietic niche." 
Bone Marrow Transplant 39(1): 11-23. 
Holmes, C. and W. L. Stanford (2007). "Concise review: stem cell antigen-1: expression, 
function, and enigma." Stem Cells 25(6): 1339-47. 
Huang, X., S. Cho, et al. (2007). "Hematopoietic stem cells: generation and self-
renewal." Cell Death Differ 14(11): 1851-9. 
Huelsken, J. and J. Behrens (2002). "The Wnt signalling pathway." J Cell Sci 115(Pt 21): 
3977-8. 
Ito, C. Y., C. Y. Li, et al. (2003). "Hematopoietic stem cell and progenitor defects in Sca-
1/Ly-6A-null mice." Blood 101(2): 517-23. 
Ivanova, N. B., J. T. Dimos, et al. (2002). "A stem cell molecular signature." Science 
298(5593): 601-4. 
Kamminga, L. M., I. Akkerman, et al. (2000). "Autonomous behavior of hematopoietic 
stem cells." Exp Hematol 28(12): 1451-9. 
Kamminga, L. M. and G. de Haan (2006). "Cellular memory and hematopoietic stem cell 
aging." Stem Cells 24(5): 1143-9. 
Kamminga, L. M., R. van Os, et al. (2005). "Impaired hematopoietic stem cell 
functioning after serial transplantation and during normal aging." Stem Cells 
23(1): 82-92. 
Karakelides, H. and K. S. Nair (2005). "Sarcopenia of aging and its metabolic impact." 
Curr Top Dev Biol 68: 123-48. 
Katz, F. E., R. Tindle, et al. (1985). "Identification of a membrane glycoprotein 
associated with haemopoietic progenitor cells." Leuk Res 9(2): 191-8. 
Kelly, B. L. and A. Ferreira (2007). "Beta-amyloid disrupted synaptic vesicle endocytosis 
in cultured hippocampal neurons." Neuroscience 147(1): 60-70. 
Kenyon, J. and S. L. Gerson (2007). "The role of DNA damage repair in aging of adult 
stem cells." Nucleic Acids Res 35(22): 7557-65. 
Kida, Y., K. Asahina, et al. (2007). "Twist relates to tubular epithelial-mesenchymal 
transition and interstitial fibrogenesis in the obstructed kidney." J Histochem 
Cytochem 55(7): 661-73. 
Kindt, G., Osbourne (2007). "Kuby Immunology." 
 49 
 
Kirillova, I., E. Gussoni, et al. (2007). "Myogenic reprogramming of retina-derived cells 
following their spontaneous fusion with myotubes." Dev Biol 311(2): 449-63. 
Komuro, H., R. Saihara, et al. (2007). "Identification of side population cells (stem-like 
cell population) in pediatric solid tumor cell lines." J Pediatr Surg 42(12): 2040-5. 
Kondo, M., I. L. Weissman, et al. (1997). "Identification of clonogenic common 
lymphoid progenitors in mouse bone marrow." Cell 91(5): 661-72. 
Krause, D. S., T. Ito, et al. (1994). "Characterization of murine CD34, a marker for 
hematopoietic progenitor and stem cells." Blood 84(3): 691-701. 
Krtolica, A. (2005). "Stem cell: balancing aging and cancer." Int J Biochem Cell Biol 
37(5): 935-41. 
Kuang, S. B. C., Patrick Seale, Michael Huh, and Michael A. Rudnicki (2006). "Distinct 
roles for Pax7 and Pax3 in adult regenerative myogenesis  
". 
Lako, M., S. Lindsay, et al. (2001). "Characterisation of Wnt gene expression during the 
differentiation of murine embryonic stem cells in vitro: role of Wnt3 in enhancing 
haematopoietic differentiation." Mech Dev 103(1-2): 49-59. 
Le Grand, F. and M. Rudnicki (2007). "Satellite and stem cells in muscle growth and 
repair." Development 134(22): 3953-7. 
Le Grand, F. and M. A. Rudnicki (2007). "Skeletal muscle satellite cells and adult 
myogenesis." Curr Opin Cell Biol 19(6): 628-33. 
Liang, Y., G. Van Zant, et al. (2005). "Effects of aging on the homing and engraftment of 
murine hematopoietic stem and progenitor cells." Blood 106(4): 1479-87. 
Lichtman, M. A. and J. M. Rowe (2004). "The relationship of patient age to the 
pathobiology of the clonal myeloid diseases." Semin Oncol 31(2): 185-97. 
Linton, P. J. and K. Dorshkind (2004). "Age-related changes in lymphocyte development 
and function." Nat Immunol 5(2): 133-9. 
Longobardi (2001). Flow Cytometry  First Principles  
Lorenzon, P., E. Bandi, et al. (2004). "Ageing affects the differentiation potential of 
human myoblasts." Exp Gerontol 39(10): 1545-54. 
Mao, P., S. Wang, et al. (2004). "Umbilical cord blood transplant for adult patients with 
severe aplastic anemia using anti-lymphocyte globulin and cyclophosphamide as 
conditioning therapy." Bone Marrow Transplant 33(1): 33-8. 
McKinnell, I. W., J. Ishibashi, et al. (2008). "Pax7 activates myogenic genes by 
recruitment of a histone methyltransferase complex." Nat Cell Biol 10(1): 77-84. 
McKinney-Freeman, K. A. J., Fernando D. Camargo, Giuliana Ferrari, Fulvio 
Mavilio,and Margaret A. Goodell (2002). "Muscle-derived hematopoietic stem 
cells are 
hematopoietic in origin." PNAS 99: 1341-1346. 
Megeney, L. A., B. Kablar, et al. (1996). "MyoD is required for myogenic stem cell 
function in adult skeletal muscle." Genes Dev 10(10): 1173-83. 
Michallet, M., T. Philip, et al. (2000). "Transplantation with selected autologous 
peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple 
myeloma: impact of HSC dose on engraftment, safety, and immune 
reconstitution." Exp Hematol 28(7): 858-70. 
 50 
 
Miles, C., M. J. Sanchez, et al. (1997). "Expression of the Ly-6E.1 (Sca-1) transgene in 
adult hematopoietic stem cells and the developing mouse embryo." Development 
124(2): 537-47. 
Mitchell, P. O., T. Mills, et al. (2005). "Sca-1 negatively regulates proliferation and 
differentiation of muscle cells." Dev Biol 283(1): 240-52. 
Montarras, D., J. Morgan, et al. (2005). "Direct isolation of satellite cells for skeletal 
muscle regeneration." Science 309(5743): 2064-7. 
Morgan, J. E., E. P. Hoffman, et al. (1990). "Normal myogenic cells from newborn mice 
restore normal histology to degenerating muscles of the mdx mouse." J Cell Biol 
111(6 Pt 1): 2437-49. 
Morrison, S. J., N. M. Shah, et al. (1997). "Regulatory mechanisms in stem cell biology." 
Cell 88(3): 287-98. 
Morrison, S. J., A. M. Wandycz, et al. (1996). "The aging of hematopoietic stem cells." 
Nat Med 2(9): 1011-6. 
Morrison, S. J., D. E. Wright, et al. (1997). "Hematopoietic stem cells: challenges to 
expectations." Curr Opin Immunol 9(2): 216-21. 
Muller-Sieburg, C. E. and R. Riblet (1996). "Genetic control of the frequency of 
hematopoietic stem cells in mice: mapping of a candidate locus to chromosome 
1." J Exp Med 183(3): 1141-50. 
Musaro, A., K. J. McCullagh, et al. (1999). "IGF-1 induces skeletal myocyte hypertrophy 
through calcineurin in association with GATA-2 and NF-ATc1." Nature 
400(6744): 581-5. 
Negrin, R. S., K. Atkinson, et al. (2000). "Transplantation of highly purified CD34+Thy-
1+ hematopoietic stem cells in patients with metastatic breast cancer." Biol Blood 
Marrow Transplant 6(3): 262-71. 
Partridge, T. (2002). "Myoblast transplantation." Neuromuscul Disord 12 Suppl 1: S3-6. 
Pavlath, G. K., D. Thaloor, et al. (1998). "Heterogeneity among muscle precursor cells in 
adult skeletal muscles with differing regenerative capacities." Dev Dyn 212(4): 
495-508. 
Payne, T. R., H. Oshima, et al. (2005). "Regeneration of dystrophin-expressing myocytes 
in the mdx heart by skeletal muscle stem cells." Gene Ther 12(16): 1264-74. 
Polesskaya, A., P. Seale, et al. (2003). "Wnt signaling induces the myogenic specification 
of resident CD45+ adult stem cells during muscle regeneration." Cell 113(7): 841-
52. 
Rando, T. A. (2006). "Stem cells, ageing and the quest for immortality." Nature 
441(7097): 1080-6. 
Ren, M. and L. Mu (2005). "Intrinsic properties of the adult human mylohyoid muscle: 
neural organization, fiber-type distribution, and myosin heavy chain expression." 
Dysphagia 20(3): 182-94. 
Reya, T., S. J. Morrison, et al. (2001). "Stem cells, cancer, and cancer stem cells." Nature 
414(6859): 105-11. 
Roeder, I., L. M. Kamminga, et al. (2005). "Competitive clonal hematopoiesis in mouse 
chimeras explained by a stochastic model of stem cell organization." Blood 
105(2): 609-16. 
Ross, S. E., N. Hemati, et al. (2000). "Inhibition of adipogenesis by Wnt signaling." 
Science 289(5481): 950-3. 
 51 
 
Schultz, E. and B. H. Lipton (1982). "Skeletal muscle satellite cells: changes in 
proliferation potential as a function of age." Mech Ageing Dev 20(4): 377-83. 
Seale, P., L. A. Sabourin, et al. (2000). "Pax7 is required for the specification of 
myogenic satellite cells." Cell 102(6): 777-86. 
Sebille, A. (2005). "[Cell therapy prospects in Duchenne muscular dystrophy]." J Soc 
Biol 199(1): 13-6. 
Shapiro (2003). "Practical Flow Cytometry." 
Sharma, S., R. Cabana, et al. (2008). "Cellular volume and marker expression in human 
peripheral blood apheresis stem cells." Cytometry A 73A(2): 160-167. 
Sharpless, N. E. and R. A. DePinho (2007). "How stem cells age and why this makes us 
grow old." Nat Rev Mol Cell Biol 8(9): 703-13. 
Shefer, G., D. P. Van de Mark, et al. (2006). "Satellite-cell pool size does matter: 
defining the myogenic potency of aging skeletal muscle." Dev Biol 294(1): 50-66. 
Shimizu, H., M. A. Julius, et al. (1997). "Transformation by Wnt family proteins 
correlates with regulation of beta-catenin." Cell Growth Differ 8(12): 1349-58. 
Shizuru, J. A., R. S. Negrin, et al. (2005). "Hematopoietic stem and progenitor cells: 
clinical and preclinical regeneration of the hematolymphoid system." Annu Rev 
Med 56: 509-38. 
Siminovitch, L., E. A. McCulloch, et al. (1963). "The Distribution of Colony-Forming 
Cells among Spleen Colonies." J Cell Physiol 62: 327-36. 
Spangrude, G. J., Y. Aihara, et al. (1988). "The stem cell antigens Sca-1 and Sca-2 
subdivide thymic and peripheral T lymphocytes into unique subsets." J Immunol 
141(11): 3697-707. 
Spangrude, G. J., S. Heimfeld, et al. (1988). "Purification and characterization of mouse 
hematopoietic stem cells." Science 241(4861): 58-62. 
Springer, M. L. (2002). "VEGF therapy in heart disease: for better or for worse?" Drug 
Discov Today 7(4): 209-11. 
Stockdale, F. E. and H. Holtzer (1961). "DNA synthesis and myogenesis." Exp Cell Res 
24: 508-20. 
Stredrick, D. L., A. H. Stokes, et al. (2004). "Manganese-induced cytotoxicity in 
dopamine-producing cells." Neurotoxicology 25(4): 543-53. 
Suda, J., T. Sudo, et al. (1992). "Two types of murine CD34 mRNA generated by 
alternative splicing." Blood 79(9): 2288-95. 
Sudo, K., H. Ema, et al. (2000). "Age-associated characteristics of murine hematopoietic 
stem cells." J Exp Med 192(9): 1273-80. 
Tamaki, T., A. Akatsuka, et al. (2002). "Identification of myogenic-endothelial 
progenitor cells in the interstitial spaces of skeletal muscle." J Cell Biol 157(4): 
571-7. 
Taylor-Jones, J. M., R. E. McGehee, et al. (2002). "Activation of an adipogenic program 
in adult myoblasts with age." Mech Ageing Dev 123(6): 649-61. 
Thomas, M. L. (1989). "The leukocyte common antigen family." Annu Rev Immunol 7: 
339-69. 
Till, J. E. and C. E. Mc (1961). "A direct measurement of the radiation sensitivity of 
normal mouse bone marrow cells." Radiat Res 14: 213-22. 
Ueno, H. and I. L. Weissman (2007). "Stem cells: blood lines from embryo to adult." 
Nature 446(7139): 996-7. 
 52 
 
Uher, F. (2000). "[The origin, development and aging of hematopoietic stem cells]." Orv 
Hetil 141(7): 347-52. 
van de Rijn, M., S. Heimfeld, et al. (1989). "Mouse hematopoietic stem-cell antigen Sca-
1 is a member of the Ly-6 antigen family." Proc Natl Acad Sci U S A 86(12): 
4634-8. 
Van Den Berg, D. J., A. K. Sharma, et al. (1998). "Role of members of the Wnt gene 
family in human hematopoiesis." Blood 92(9): 3189-202. 
Vertino, A. M., J. M. Taylor-Jones, et al. (2005). "Wnt10b deficiency promotes 
coexpression of myogenic and adipogenic programs in myoblasts." Mol Biol Cell 
16(4): 2039-48. 
Virts, E., D. Barritt, et al. (1997). "Murine mast cells and monocytes express distinctive 
sets of CD45 isoforms." Mol Immunol 34(16-17): 1191-7. 
Vose, J. M., M. J. Zhang, et al. (2001). "Autologous transplantation for diffuse aggressive 
non-Hodgkin's lymphoma in patients never achieving remission: a report from the 
Autologous Blood and Marrow Transplant Registry." J Clin Oncol 19(2): 406-13. 
Weissman, I. L. (2000). "Translating stem and progenitor cell biology to the clinic: 
barriers and opportunities." Science 287(5457): 1442-6. 
Wiley-Liss (2007). "Current protocols in Cytometry." 
Willert, K., J. D. Brown, et al. (2003). "Wnt proteins are lipid-modified and can act as 
stem cell growth factors." Nature 423(6938): 448-52. 
Willert, K. and R. Nusse (1998). "Beta-catenin: a key mediator of Wnt signaling." Curr 
Opin Genet Dev 8(1): 95-102. 
Wilson, A. and A. Trumpp (2006). "Bone-marrow haematopoietic-stem-cell niches." Nat 
Rev Immunol 6(2): 93-106. 
Wong, S. H., K. N. Lowes, et al. (2007). "Evaluation of Sca-1 and c-Kit as selective 
markers for muscle remodelling by nonhemopoietic bone marrow cells." Stem 
Cells 25(6): 1364-74. 
Wood, H. B. M., G. Healy, L.Enver, T.Morriss-Kay, G. M. (1997). "CD34 expression 
patterns during early mouse development are related to modes of blood vessel 
formation and reveal additional sites of hematopoiesis." Blood 90(6): 2300-11. 
Yablonka-Reuveni, Z. and A. J. Rivera (1994). "Temporal expression of regulatory and 
structural muscle proteins during myogenesis of satellite cells on isolated adult rat 
fibers." Dev Biol 164(2): 588-603. 
Zammit, P. and J. Beauchamp (2001). "The skeletal muscle satellite cell: stem cell or son 
of stem cell?" Differentiation 68(4-5): 193-204. 
Zammit, P. S., L. Heslop, et al. (2002). "Kinetics of myoblast proliferation show that 
resident satellite cells are competent to fully regenerate skeletal muscle fibers." 
Exp Cell Res 281(1): 39-49. 
Zammit, P. S., F. Relaix, et al. (2006). "Pax7 and myogenic progression in skeletal 
muscle satellite cells." J Cell Sci 119(Pt 9): 1824-32. 
Zammit, P. S., Terence A. Partridge, and Zipora Yablonka-Reuveni (2006). "The Skeletal 
Muscle Satellite Cell: The Stem Cell That Came in From the Cold." Journal of 
Histochemistry & Cytochemistry 54: 1177-1191. 
Zipori, D. and J. Honigwachs-Sha'anani (1992). "Growth restrictions in the regulation of 
haemopoiesis." Baillieres Clin Haematol 5(3): 741-52. 
 53 
 
Zulewski, H. (2007). "Stem cells with potential to generate insulin-producing cells in 
man." Swiss Med Wkly 137 Suppl 155: 60S-67S. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 54 
 
VITA 
 
 
 
Sonia Angela Richards-Malcolm 
 
 
 
 
Personal Data 
 
Date of Birth    June 26, 1972 
Place of Birth    Kingston, Jamaica 
 
Education: 
 
Graduate Education:   University of Kentucky 
     Lexington, Kentucky (2006- present) 
     College of Health Sciences 
     Graduate Student 
 
 
     University of Technology, Jamaica 
     Kingston, Jamaica (2004-2005) 
     Department of Education 
Postgraduate Diploma, Education  
 
University of the West Indies, Mona  
     Kingston, Jamaica (2002-2004) 
     Department of Community Health & Psychiatry 
Master, Public Health specializing Health 
Education/Promotion  
 
Undergraduate:   Northern Caribbean University 
Mandeville, Jamaica (1998-2002) 
Department of Biology, Chemistry &Medical     
Technology 
Bachelor of Science, Medical Technology  
 
 
 
 55 
 
Professional Experience: 
 
2003- present    Lecturer, Department of  Medical Technology 
     School of Pharmacy & Health Science 
     University of Technology, Jamaica 
 Kingston, Jamaica  
 
2004- present     Research and Phlebotomy Coordinator,  
     School of Pharmacy & Health Science 
     University of Technology, Jamaica 
 Kingston, Jamaica  
 
2002-2006    Medical Technologist 
      Department of Pathology  
     University Hospital of the West Indies, Mona 
 Kingston, Jamaica  
 
2001-2002    Health Fair Manager 
International Centre for Environmental & Nuclear 
Sciences (ICENS) University of the West Indies, 
Mona 
Kingston, Jamaica  
 
  
1998-2001    Laboratory Manager 
     Diagnostic Laboratory, Northern Caribbean  
                                                             University 
Mandeville, Jamaica 
 
 
1998-2001    Teaching Assistant  
     Diagnostic Laboratory, Northern Caribbean  
                                                             University 
Mandeville, Jamaica 
 
1992-1997    Laboratory Technician 
      Department of Pathology  
     University Hospital of the West Indies, Mona 
Kingston, Jamaica  
 
1990-1992    Laboratory Assistant 
      Caledonia medical laboratories 
     Kingston, Jamaica  
     
 
 
 56 
 
Professional Affiliations: 
 
1999-2001 Northern Caribbean University Science 
Association, president 
 
2002- present    Caribbean Medical Technologists Association,  
Member 
 
2002- present     Professional Supplementary to Medicine, member 
 
2002- present    Northern Caribbean University Alumni        
                                                            Association, member 
 
2004-2006  Caribbean Medical Technologists Association,  
                                                             Public Relations Officer 
 
2004-present    University of the West Indies Alumni Association,  
                                                            member 
2007-present    American Association of Blood Banking, member 
 
2007-present     Delta Epsilon Iota Academic Honor Society,  
                                                            member 
 
Honours and Awards: 
 
Fulbright Latin American Scholarship Programme of American Universities (LASPAU) 
Faculty Scholarship Award (2006-2008) 
United States Department of State’s Bureau of Educational and Cultural Affairs 
 
Kentucky Graduate Scholarship (2006-2008) 
 University of Kentucky Graduate School, Lexington, Kentucky 
 
Philanthropic and Educational Organization (P.E.O) International Peace Scholarship for 
Women Award (2007-2008) 
Philanthropic and Educational Organization (P.E.O) International Headquarters, Des 
Moines, Iowa 
 
Academic Excellence and strong leadership Qualities Life Time Membership Award 
(2008) 
Delta Epsilon Iota Academic Honor Society Headquarters, Atlanta, Georgia 
 
 
 
 
 
 
 57 
 
Publications: 
 
Hidestrand Mats, Richards-Malcolm Sonia, Gurley Cathy M., Nolen Greg, Grimes 
Barry, Van Zant Gary and Peterson Charlotte A. 
Sca-1 expressing non-myogenic cells contributes to fibrosis in aged skeletal muscle  In 
press 2008. 
 
Richards-Malcolm Sonia Blood donation actions and intent among University students, 
West Indies Medical Journal Supplement Vol.53 (Suppl. 2) April 2004.  
 
Richards-Malcolm Sonia The role of Medical Technologist in Health Care Delivery, 
American Medical Technologist Journal 20(1), March 2003.  
 
Richards-Malcolm Sonia.Factors influencing blood donation actions and intent among 
students at the University of Technology, Jamaica West Indies medical Journal 
Supplement Vol.52: (Suppl 6) Nov 2003. 
 58 
 
 1 
